PHAT
Income statement / Annual
Last year (2023), Phathom Pharmaceuticals, Inc.'s total revenue was $682,000.00,
and the percentage change from the previous year is not available.
In 2023, Phathom Pharmaceuticals, Inc.'s net income was -$201.59 M.
See Phathom Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$682,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$167,000.00 |
$620,000.00 |
$521,000.00 |
$300,000.00 |
$8,000.00 |
$0.00 |
| Gross Profit |
$515,000.00 |
-$620,000.00 |
-$521,000.00 |
-$300,000.00 |
-$8,000.00 |
$0.00 |
| Gross Profit Ratio |
0.76 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$49.90 M
|
$71.44 M
|
$72.34 M
|
$98.15 M
|
$99.27 M
|
$20,000.00
|
| General & Administrative
Expenses |
$0.00
|
$101.00 M
|
$62.74 M
|
$27.52 M
|
$6.94 M
|
$1.21 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$117.93 M
|
$101.00 M
|
$62.74 M
|
$27.52 M
|
$6.94 M
|
$1.21 M
|
| Other Expenses |
$0.00 |
-$110,000.00 |
-$2.06 M |
-$8,000.00 |
-$49.56 M |
-$50,000.00 |
| Operating Expenses |
$167.83 M |
$172.44 M |
$135.08 M |
$125.67 M |
$106.22 M |
$1.23 M |
| Cost And Expenses |
$167.99 M |
$172.44 M |
$135.08 M |
$125.67 M |
$106.22 M |
$1.23 M |
| Interest Income |
$7.88 M |
$2.13 M |
$41,000.00 |
$1.09 M |
$1.09 M |
$0.00 |
| Interest Expense |
$41.97 M |
$27.31 M |
$6.79 M |
$4.58 M |
$4.18 M |
$13,000.00 |
| Depreciation &
Amortization |
$575,000.00
|
$620,000.00
|
$521,000.00
|
$300,000.00
|
$8,000.00
|
$1.23 M
|
| EBITDA |
-$159.05 M
|
-$171.82 M
|
-$134.56 M
|
-$124.19 M
|
-$250.95 M
|
-$50,000.00
|
| EBITDA Ratio |
-233.21 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-245.33
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$34.28 M
|
-$25.28 M
|
-$8.80 M
|
-$3.40 M
|
-$148.92 M
|
-$63,000.00
|
| Income Before Tax |
-$201.59 M |
-$197.72 M |
-$143.88 M |
-$129.07 M |
-$255.13 M |
-$1.29 M |
| Income Before Tax Ratio
|
-295.59
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$25.28 M |
$4.21 M |
$4.25 M |
-$45.39 M |
$13,000.00 |
| Net Income |
-$201.59 M |
-$223.01 M |
-$148.09 M |
-$133.32 M |
-$209.74 M |
-$1.29 M |
| Net Income Ratio |
-295.59 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-3.93 |
-5.7 |
-4 |
-4.01 |
-8.48 |
-0.15 |
| EPS Diluted |
-3.93 |
-5.7 |
-4 |
-4.01 |
-8.48 |
-0.15 |
| Weighted Average Shares
Out |
$51.29 M
|
$39.12 M
|
$37.00 M
|
$33.23 M
|
$24.73 M
|
$8.58 M
|
| Weighted Average Shares
Out Diluted |
$51.29 M
|
$39.12 M
|
$37.00 M
|
$33.23 M
|
$24.73 M
|
$8.58 M
|
| Link |
|
|
|
|
|
|
